Newbury Pharmaceuticals AB (NEWBRY) - Total Assets
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) holds total assets worth Skr76.58 Million SEK (≈ $8.24 Million USD) as of November 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Newbury Pharmaceuticals AB (NEWBRY) net assets for net asset value and shareholders' equity analysis.
Newbury Pharmaceuticals AB - Total Assets Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's total assets have evolved over time, based on quarterly financial data.
Newbury Pharmaceuticals AB - Asset Composition Analysis
Current Asset Composition (August 2024)
Newbury Pharmaceuticals AB's total assets of Skr76.58 Million consist of 48.4% current assets and 51.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 16.8% |
| Accounts Receivable | Skr23.68 Million | 26.1% |
| Inventory | Skr5.00 Million | 5.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr45.64 Million | 50.2% |
| Goodwill | Skr1.26 Million | 1.4% |
Asset Composition Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Newbury Pharmaceuticals AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Newbury Pharmaceuticals AB's current assets represent 48.4% of total assets in 2024, an increase from 36.8% in 2021.
- Cash Position: Cash and equivalents constituted 16.8% of total assets in 2024, down from 30.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, a decrease from 62.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 50.2% of total assets.
Newbury Pharmaceuticals AB Competitors by Total Assets
Key competitors of Newbury Pharmaceuticals AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Newbury Pharmaceuticals AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.25 | 1.29 | 3.63 |
| Quick Ratio | 0.99 | 1.15 | 3.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr9.18 Million | Skr9.34 Million | Skr11.43 Million |
Newbury Pharmaceuticals AB - Advanced Valuation Insights
This section examines the relationship between Newbury Pharmaceuticals AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 24.6% |
| Total Assets | Skr90.87 Million |
| Market Capitalization | $4.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Newbury Pharmaceuticals AB's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Newbury Pharmaceuticals AB's assets grew by 24.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual total assets of Newbury Pharmaceuticals AB from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-08-31 | Skr90.87 Million ≈ $9.78 Million |
+24.62% |
| 2023-08-31 | Skr72.92 Million ≈ $7.85 Million |
-16.09% |
| 2022-08-31 | Skr86.91 Million ≈ $9.35 Million |
+103.01% |
| 2021-08-31 | Skr42.81 Million ≈ $4.61 Million |
-- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.